NCT05094804 2023-11-02A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer AgentsOncoResponse, Inc.Phase 1/2 Unknown172 enrolled
NCT05429866 2023-03-08Immunological Variables Associated to ICI Toxicity in Cancer PatientsJules Bordet InstitutePhase 2 Unknown441 enrolled
NCT04460456 2022-06-30A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid TumorsSilverback TherapeuticsPhase 1 Unknown58 enrolled